NZ594937A - Beloxepin, its enantiomers, and analogs thereof for the treatment of pain - Google Patents

Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Info

Publication number
NZ594937A
NZ594937A NZ594937A NZ59493709A NZ594937A NZ 594937 A NZ594937 A NZ 594937A NZ 594937 A NZ594937 A NZ 594937A NZ 59493709 A NZ59493709 A NZ 59493709A NZ 594937 A NZ594937 A NZ 594937A
Authority
NZ
New Zealand
Prior art keywords
beloxepin
pain
enantiomers
analogs
treatment
Prior art date
Application number
NZ594937A
Inventor
Bourdonnec Bertrand Le
Roland Dolle
Original Assignee
Adolor Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adolor Corp filed Critical Adolor Corp
Publication of NZ594937A publication Critical patent/NZ594937A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed is beloxepin enriched in the (-) enantiomer for treating pain, depression, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, trichotilomania, insomnia related to opioid withdrawal, and attention deficit hyperactivity disorder and pre-menstral syndrome or dysphoria and fibromyalgia.
NZ594937A 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain NZ594937A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2991508P 2008-02-19 2008-02-19
US2991308P 2008-02-19 2008-02-19
US2991608P 2008-02-19 2008-02-19
US5092108P 2008-05-06 2008-05-06
PCT/US2009/034461 WO2009105507A2 (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Publications (1)

Publication Number Publication Date
NZ594937A true NZ594937A (en) 2013-03-28

Family

ID=40986169

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ587896A NZ587896A (en) 2008-02-19 2009-02-19 Enantiomers of beloxepin, and the use of beloxepin and its enantiomers to treat pain and other disorders
NZ594937A NZ594937A (en) 2008-02-19 2009-02-19 Beloxepin, its enantiomers, and analogs thereof for the treatment of pain

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ587896A NZ587896A (en) 2008-02-19 2009-02-19 Enantiomers of beloxepin, and the use of beloxepin and its enantiomers to treat pain and other disorders

Country Status (11)

Country Link
EP (1) EP2285818A4 (en)
JP (1) JP2011512414A (en)
KR (1) KR20100137473A (en)
CN (1) CN102007139A (en)
AU (1) AU2009215541A1 (en)
BR (1) BRPI0908098A2 (en)
CA (1) CA2715192A1 (en)
IL (1) IL207668A0 (en)
MX (1) MX2010009110A (en)
NZ (2) NZ587896A (en)
WO (1) WO2009105507A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
CA3204599A1 (en) 2015-02-25 2016-09-01 The Regents Of The University Of California 5ht agonists for treating disorders
CN106243096B (en) * 2016-07-29 2019-11-29 上海璃道医药科技有限公司 The new application of tricyclic drugs
US10966938B2 (en) 2019-01-04 2021-04-06 Jonand4, Llc Composition and method for preventing or treating hangover symptoms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE62754B1 (en) 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
US5663178A (en) 1995-02-06 1997-09-02 Eli Lilly And Company Tetrahydro-beta carbolines
TW440563B (en) * 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
US5952331A (en) 1996-05-23 1999-09-14 Syntex (Usa) Inc. Aryl pyrimidine derivatives
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
GB0019950D0 (en) 2000-08-12 2000-09-27 Smithkline Beecham Plc Compounds
AU2003283656A1 (en) * 2002-12-11 2004-06-30 Pharmacia & Upjohn Company Llc Combination for the treatment of adhd
EP1685115A1 (en) * 2003-11-03 2006-08-02 Warner-Lambert Company LLC Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
CA2588595A1 (en) * 2004-12-13 2006-06-22 Arena Pharmaceuticals, Inc. N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto
US7915249B2 (en) * 2005-01-27 2011-03-29 Janssen Pharmaceutical Nv Heterocyclic tetracyclic tetrahydrofuran derivatives as 5HT2 inhibitors in the treatment of CNS disorders
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
PE20070544A1 (en) * 2005-09-29 2007-07-26 Wyeth Corp BENZOTIADIAZOLYLPHENYLALKYLAMINE DERIVATIVES
CA2647835A1 (en) * 2006-03-28 2007-10-04 Neopro Labs, Llc Methods and compositions for treating conditions
GB0608655D0 (en) * 2006-05-03 2006-06-14 Merck Sharp & Dohme Therapeutic Treatment
WO2007142923A1 (en) * 2006-05-31 2007-12-13 Avigen, Inc. Mif inhibitors for treating neuropathic pain and associated syndromes

Also Published As

Publication number Publication date
EP2285818A2 (en) 2011-02-23
MX2010009110A (en) 2010-11-30
IL207668A0 (en) 2010-12-30
NZ587896A (en) 2011-09-30
KR20100137473A (en) 2010-12-30
JP2011512414A (en) 2011-04-21
WO2009105507A2 (en) 2009-08-27
CA2715192A1 (en) 2009-08-27
AU2009215541A1 (en) 2009-08-27
CN102007139A (en) 2011-04-06
BRPI0908098A2 (en) 2015-08-18
WO2009105507A3 (en) 2010-01-14
EP2285818A4 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
EA201100748A1 (en) PYRAZINE COMPOUNDS AS PHOSPHODESTERASE INHIBITORS 10
DE602008004245D1 (en) IMPROVED METHOD FOR THE PRODUCTION OF 6-ALPHA-HYDROXY-N-ALKYLATED OPIATES
MX2012000150A (en) Biological methods for preparing adipic acid.
TN2012000549A1 (en) Substituted 5-fluoro-1h-pyrazolopyridines and use thereof
JO2756B1 (en) 4T 4-(4- Cyano-2-thioaryl)dihydropyrimidinones and use thereof
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
MY178338A (en) Compositions and methods for biological production of lactate from c1 compounds using lactate dehydrogenase transformants
MX2011009369A (en) Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators.
NZ594937A (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
UA107812C2 (en) Oktahidropirolo disubstituted [3,4-c] pyrrole receptors as orexin modulators
MX351133B (en) Method for treating osteoporosis.
MX2012000583A (en) Method for producing chiral 3-triazolyl-sulfoxide derivatives.
MX2013003309A (en) Substituted benzamide compounds.
EA201270280A1 (en) Pyrimidine Compounds as Inhibitors in the Treatment of Tuberculosis
MY158569A (en) Treatment of biofuels
NZ730334A (en) Substituted 2-azabicycles and their use as orexin receptor modulators
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
UA102515C2 (en) Novel dosage form
MX337526B (en) Processes for the manufacture of macrocyclic depsipeptides and new intermediates.
BR112014002859A2 (en) post-processing purification for production of lactone gamma-butyr
MY170615A (en) Novel matting agent for uv varnishes
IN2014DN10741A (en)
AR078986A1 (en) A METHOD TO PROMOTE THE DENSITY OF DENDRITIC THORNS
MX2010009931A (en) Process for the preparation of 2-amino-2- [2- (4-c3-c21-alkyl-phenyl)ethyl] propane-1, 3-diols.
EA201190313A1 (en) SUBSTITUTED PIPERIDINES

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: BELOXEPIN, ITS ENANTIOMERS, AND ANALOGS THEREOF FOR THE TREATMENT OF PAIN; FILING DATE: 31 AUG 2011; STATUS: REJECTED; PUBLICATION DATE: 28 MAR 2013;

Effective date: 20130408

AABA Application abandoned